Skip to main content

Table 3 Certainty in the assessment of efficacy outcomes for anti-calcitonin gene-related peptide monoclonal antibodies for prevention in episodic migraine

From: Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

  Certainty assessment Certainty
Number of studies Study design Risk of bias Inconsistency Indirectness Imprecision Other considerations
Eptinezumab
 1000 mg quarterly ev 1 RCT not serious seriousa not serious seriousb none LOW
Erenumab
 70 monthly sc (except functional improvement) 3 RCT not serious not serious not serious not serious none HIGH
 70 monthly sc (functional improvement) 1 RCT not serious seriousa not serious not serious none MEDIUM
 140 monthly sc 1 RCT not serious seriousa not serious not serious none MEDIUM
Fremanezumab
 225 monthly sc 2 RCT not serious not serious not serious not serious none HIGH
 675 quarterly sc 1 RCT not serious seriousa not serious not serious none MEDIUM
Galcanezumab
 240 mg ld + 120 mg monthly sc 2 RCT not serious not serious not serious not serious none HIGH
 240 mg monthly sc 2 RCT not serious not serious not serious not serious none HIGH
  1. sc: subcutaneous; ev: endovenous; RCT: randomized controlled trial. aInconsistency because of lack of replication; bImprecision because of exploratory study. The inconsistency for the Galcanezumab study was changed from serios to not serios, and the certainty from medium to high